This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Voyager Therapeutics (VYGR) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 132.95% and 777.85%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Voyager Therapeutics (VYGR) Q2 Earnings Expected to Decline
by Zacks Equity Research
Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -2.53% and 73.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Voyager Therapeutics (VYGR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie Extends Deal With Voyager to Make Parkinson's Drugs
by Zacks Equity Research
AbbVie (ABBV) expands its collaboration with Voyager Therapeutics to develop potential vectorized antibodies for Parkinson's disease (PD) and other synucleinopathies.
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3
by Zacks Equity Research
Dr. Reddy's earnings and sales rise year over year in the third-quarter of fiscal 2019.
Voyager Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Voyager Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Voyager Therapeutics (VYGR) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -26.98% and -14.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Voyager Therapeutics (VYGR) Ahead of Earnings?
by Zacks Equity Research
Voyager Therapeutics (VYGR) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Abbvie's Uterine Fibrosis Candidate Meets Goal in Study
by Zacks Equity Research
AbbVie's (ABBV) phase III study of its late stage candidate elagolix meets its primary endpoint in women with uterine fibroids.
Ophthotech Begins Phase II Zimura Study in Stargardt Disease
by Zacks Equity Research
Ophthotech (OPHT) is focusing on Zimura following the failure of the Fovista studies.
Voyager Therapeutics (VYGR) Jumps: Stock Rises 7.8%
by Zacks Equity Research
Voyager Therapeutics (VYGR) was a big mover last session, as the company saw its shares nearly 8% on the day amid huge volumes.
Voyager Therapeutics (VYGR) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Voyager Therapeutics, Inc. (VYGR) has been struggling lately, but the selling pressure may be coming to an end soon